Scroll Back to Top
Accessibility
Accessibility
Provider showing a tablet to a patient

Labcorp Plasma Complete™: Designed for advanced solid tumors

A comprehensive ctDNA liquid biopsy test for patients with advanced solid tumors that evaluates 521 genes to inform the selection of targeted treatment options.

Get in Touch How to Order
supporting image

Why choose Labcorp Plasma Complete

 

Icon of a clipboard with a medical cross

Expands treatment options

Maximize treatment options with an extensive panel that covers both established and emerging biomarkers

Icon of three gears

Streamlines experience

Integrate plasma-based genomic testing into your clinical workflows to enhance a comprehensive molecular assessment

Icon of a clock at 4

Delivers timely results

Receive easy to read and comprehensive results

Examples of clinical scenarios to order Labcorp Plasma Complete3,4
 

  • obtaining tissue via biopsy is technically challenging

  • limited archived tumor tissue is available

  • rapid results are needed for treatment decisions

  • patient is progressing on current therapy 

  • tissue biopsy test result is unavailable due to specimen quality or quantity insufficiency

Labcorp Plasma Complete educational content

What is Labcorp Plasma Complete?

Labcorp Plasma Complete is a 521-gene panel ctDNA liquid biopsy test for all advanced solid tumors, enabling the selection of targeted treatment options when tissue-based testing is not feasible. As a comprehensive NGS test, it delivers clear results for biomarkers associated with FDA-approved, guideline-driven, and investigational therapies.

 


Labcorp Plasma Complete test components2
 

Icon of a DNA strand

Genomic alterations

SNVs and Indels: 521 genes*
Amplifications: 12 genes (CCND1, CDK4, CD274, EGFR, ERBB2 (HER2), FGF19, FGF3, FGF4, FGFR1, MDM2, MET, MYC)
Translocations: 12 genes (ALK, BRAF, ETV6, EWDR1, FGFR2, FGFR3, NTRK1, NTRK 2, NTRK 3, RET, ROS1, TMPRSS2)

*SNVs-single nucleotide variants; indels-insertions/deletions; blood tumor mutational burden (bTMB)

Icon of a dna strand with a broken link

Genomic signatures

Microsatellite instability (MSI) status and blood tumor mutational burden (bTMB)

Icon of a clipboard with checks

Clinical trial identification

Geocoded clinical trials that may be considered for biomarker-directed treatment

For patients with unresectable advanced‑stage (Stage III) or metastatic (Stage IV) solid tumors

Specimen requirements and storage
 

Specimen Requirements

Collect a total of 20 mL of whole blood into the 2 Streck BCT® tubes supplied in the Labcorp Oncology Liquid Biopsy Kit
Only the Labcorp Oncology Liquid Biopsy kit can be used for collection and shipping
Sample shipment to Labcorp Oncology must occur within 24 hours of blood draw 

Storage Instructions

Room temperature. Do not refrigerate or freeze. Keep out of direct sunlight

See test menu for additional information


Labcorp Plasma Complete performance characteristics

VariantReportable RangeAnalytical Sensitivity (LoD)*Analytical Specificity**
SNVs≥0.1% VAF†0.38% VAF†> 99.99%
Indels≥0.1% VAF†0.43% VAF†100%
CNAs≥1.2-fold1.63-fold100%
Translocations≥2 fusion reads0.35% FRF‡100%
MSI***MSI-HighN/A100%
bTMBN/AN/A100%

*Defined as the detection rate, that is, limit of detection (LoD). **Defined as 100% minus the per-sample false positive rate. ***MSI-High is detected when ≥20% tracts are unstable; FRF: fusion read fraction; VAF: variant allele fraction.
†VAF: Variant allele fraction. ‡FRF: Fusion read fraction.

Why partner with Labcorp for your oncology testing needs 
 

Comprehensive 

A full spectrum of oncology and clinical testing across the continuum of care: spanning screening, risk assessment, diagnostics, prognostics, monitoring, and surveillance, including germline and somatic testing with tissue- and liquid-based next-generation sequencing for comprehensive genomic profiling

Connected

Seamless ordering & reporting

Contracted

Broad payer coverage

Convenient

Nationwide access to patient service centers for blood draw and shipment

Labcorp Plasma Complete resources
 

Get in Touch

Labcorp Plasma Complete 

  • High Laboratory Quality Standards

  • CLIA certified and CAP accredited

Medical affairs clinical support

Our team of pathologists and oncologists is available to support you and your patients through a centralized system.

Email: [email protected]

Phone: 800-781-1259

Frequently asked questions 

  • What is a liquid biopsy?

    A liquid biopsy is a blood test that typically analyzes circulating tumor DNA (ctDNA) to provide genomic insights into a patient’s cancer without requiring an invasive procedure.

  • How is liquid biopsy different from tissue biopsy?

    While tissue biopsy provides direct analysis of tumor cells and remains a key method for diagnosis and detailed characterization, liquid biopsy has several benefits. It relies on tumor markers, like ctDNA in the blood, to provide key information regarding the cancer. It can be used when tissue is not available or is of poor quality; provides a faster turnaround time, may offer a more comprehensive view of tumor heterogeneity in metastatic disease, provide complementary information to traditional biopsy and can be performed at various times without requiring the need for additional tissue.

  • What information does a liquid biopsy provide?

    Liquid biopsy identifies key genomic alterations, including mutations, amplifications, translocations as well as immune biomarkers such as MSI status and blood based TMB. These biomarkers guide the selection of targeted treatment options and immunotherapy decisions.

  • When should I order a liquid biopsy?

    Order when you need rapid molecular insight or when tissue testing is not feasible. Common triggers include disease progression, limited tissue, or delayed results.

  • Which patients are best suited for liquid biopsy?

    Liquid biopsy delivers the most value in patients with advanced or metastatic disease, especially those progressing on therapy, lacking sufficient tissue, or needing rapid comprehensive genomic profiling results.

  • Why does liquid biopsy matter in clinical practice?

    Liquid biopsy delivers faster results than tissue NGS, supports repeat testing, captures tumor heterogeneity, and avoids risks tied to invasive biopsies.

  • What if the liquid biopsy result is negative?

    A negative result does not rule out actionable mutations. Some tumors do not shed enough DNA. Follow up with tissue testing if clinical suspicion remains.

  • Is Labcorp Plasma Complete™ covered by insurance?

    Labcorp’s Plasma Complete is a covered benefit for Medicare beneficiaries including those individuals enrolled in Medicare Advantage plans who meet criteria for testing.

    For individuals enrolled in commercial health plans, coverage varies; patients should consult with their provider and insurance plan to understand criteria and steps necessary to obtain coverage for this test.

References: 

  1. Filipska, M and Rosel, R. Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment. Molecular Oncology. 2021; 15, 1667–1682. doi.org/10.1002/1878-0261.12983
  2. Verner EL, Jackson JB, Maddox C, et al. Analytical validation of the Labcorp Plasma Complete Test, a cell-free DNA comprehensive genomic profiling tool for precision oncology. J Mol Diagn. Published online 2025. doi:10.1016/j.jmoldx.2024.12.006
  3. Sabari JK, Offin M, Stephens D, et al. A prospective study of circulating tumor dna to guide matched targeted therapy in lung cancers. J Natl Cancer Inst. 2019;111(6):575-583. doi:10.1093/jnci/djy156
  4. García-Pardo M, Makarem M, Li JJN, Kelly D, Leighl NB. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: Opportunities and challenges. Br J Cancer. 2022;127(4):592-602. doi:10.1038/s41416-022-01776-9